The exclusion criteria were a previous diagnosis of stable angina, variant angina, acute coronary syndrome, or heart failure; a history of percutaneous coronary intervention, coronary artery bypass grafting surgery, or other open-heart surgery; and current or past symptoms of angina pectoris or exertional dyspnea.
analysis, we defined plaque characteristics when two or more segments had the same plaque features.
Defining Vessel Diseases
Within the category of obstructive CAD, we further divided CCTA findings as 1-, 2-, or 3-vessel disease (VD)/left main (LM), which involved one to three arteries among the left anterior descending artery (LAD), the left circumflex artery (LCX), and the right coronary artery (RCA) systems. Stenoses in diagonal branches, obtuse marginal branches, and the posterolateral branch were considered as part of the LAD, LCX, or RCA systems, respectively. We regarded the posterior descending coronary artery as part of the LCX or RCA system, depending on the local dominance of the coronary artery.
Defining Cardiac Death and Myocardial Infarction
Cardiac death was defined as being linked to a reasonable cardiac cause based on medical records. We defined myocardial infarction as the presence of cardiac enzyme elevation (positive serum creatine kinase-MB or troponin-I levels, or an elevation in the creatine kinase level to at least two times the upper limit of the normal range) accompanied by at least one of the following parameters: prolonged chest pain requiring hospital admission; development of Q waves; or other ECG changes suggesting myocardial infarction.
Predicted Risk Categories Used for Categorical Net Reclassification Index (cNRI)
For FRS and individual risk factors, we defined the predicted risk categories as follows: (1) <2.5%; (2) 2.5% to <7.5%; (3) 7.5% to <15%; and (4) 15%. These categories were derived from a previous study with a similar follow-up period. 6 For the atherosclerotic cardiovascular disease (ASCVD) risk score, we defined risk categories as follows, regarding the follow-up time of our study: (1) <3.3%; (2) 3.3% to <5.0%; (3) 5.0% to <10%; and (4) 10%. These categories were derived from the 10-year ASCVD risk score categories used in a previous study of the elderly (<5%; 5% to <7.5%; and 7.5% to <15%). Values are numbers and percentages (%).
* Antiplatelet agents used during the follow-up period were aspirin, clopidogrel, cilostazol and triflusal.
** Statins used in this study included atorvastatin, rosuvastatin, simvastatin, pravastatin, pitavastatin, and fluvastatin. † Newly started or dose increases were considered as escalation; stopping or dose decreases were considered as de-escalation. ‡ For each drug, escalation was calculated as +1, de-escalation as -1 and maintenance as 0, and the sum of total scores of both antiplatelets and statins was used in further analyses. 
